7 research outputs found
Rationally Designed 2‑in‑1 Nanoparticles Can Overcome Adaptive Resistance in Cancer
The
development of resistance is the major cause of mortality in
cancer. Combination chemotherapy is used clinically to reduce the
probability of evolution of resistance. A similar trend toward the
use of combinations of drugs is also emerging in the application of
cancer nanomedicine. However, should a combination of two drugs be
delivered from a single nanoparticle or should they be delivered in
two different nanoparticles for maximal efficacy? We explored these
questions in the context of adaptive resistance, which emerges as
a phenotypic response of cancer cells to chemotherapy. We studied
the phenotypic dynamics of breast cancer cells under cytotoxic chemotherapeutic
stress and analyzed the data using a phenomenological mathematical
model. We demonstrate that cancer cells can develop adaptive resistance
by entering into a predetermined transitional trajectory that leads
to phenocopies of inherently chemoresistant cancer cells. Disrupting
this deterministic program requires a unique combination of inhibitors
and cytotoxic agents. Using two such combinations, we demonstrate
that a 2-in-1 nanomedicine can induce greater antitumor efficacy by
ensuring that the origins of adaptive resistance are terminated by
deterministic spatially constrained delivery of both drugs to the
target cells. In contrast, a combination of free-form drugs or two
nanoparticles, each carrying a single payload, is less effective,
arising from a stochastic distribution to cells. These findings suggest
that 2-in-1 nanomedicines could emerge as an important strategy for
targeting adaptive resistance, resulting in increased antitumor efficacy
Longitudinal biomarker analysis of infants treated with multiple courses of gentamicin without a change in serum creatinine concentration.
<p>Representative figures demonstrating the longitudinal quantification of the biomarkers KIM-1 (blue; ng/mg. uCr), NGAL (green; ng/mg. uCr), NAG (yellow; IU/mg. uCr) and serum creatinine (red; µmol/L) for three infants treated with gentamicin (A–C). Gentamicin treatment episode and length of treatment (days) are indicated by the black horizontal bar on each figure for that individual patient.</p
Baseline characteristics and clinical signs of neonates treated with gentamicin.
<p>Patients are subdivided according to gestational age. Mean biomarker values presented include samples collected both on and off gentamicin treatment over the whole time course of inclusion in the study.</p
Longitudinal biomarker analysis of infants treated with multiple courses of gentamicin with a change in serum creatinine concentration (AKI).
<p>Representative figures demonstrating the longitudinal quantification of the biomarkers KIM-1 (blue; ng/mg. uCr), NGAL (green; ng/mg. uCr), NAG (yellow; IU/mg. uCr) and serum creatinine (red; µmol/L) for three infants treated with gentamicin (A–C). Gentamicin treatment episode and length of treatment (days) are indicated by the black horizontal bar on each figure for that individual patient.</p
Association between gentamicin treatment and the change in biomarker values.
<p>The mean baseline biomarker values in the absence of any gentamicin treatment were 1.91 ng/mg uCr (95% CI 1.07, 2.76) for KIM-1, 0.13 IU/mg uCr (0.07, 0.19) for NAG, 425.4 ng/mg uCr (162.6, 688.3) for NGAL, and 62.39 µmol/l (53.1, 71.69) for creatinine.</p
Algorithm for Designing Nanoscale Supramolecular Therapeutics with Increased Anticancer Efficacy
In
the chemical world, evolution is mirrored in the origin of nanoscale
supramolecular structures from molecular subunits. The complexity
of function acquired in a supramolecular system over a molecular subunit
can be harnessed in the treatment of cancer. However, the design of
supramolecular nanostructures is hindered by a limited atomistic level
understanding of interactions between building blocks. Here, we report
the development of a computational algorithm, which we term Volvox
after the first multicellular organism, that sequentially integrates
quantum mechanical energy-state- and force-field-based models with
large-scale all-atomistic explicit water molecular dynamics simulations
to design stable nanoscale lipidic supramolecular structures. In one
example, we demonstrate that Volvox enables the design of a nanoscale
taxane supramolecular therapeutic. In another example, we demonstrate
that Volvox can be extended to optimizing the ratio of excipients
to form a stable nanoscale supramolecular therapeutic. The nanoscale
taxane supramolecular therapeutic exerts greater antitumor efficacy
than a clinically used taxane <i>in vivo</i>. Volvox can
emerge as a powerful tool in the design of nanoscale supramolecular
therapeutics for effective treatment of cancer
Algorithm for Designing Nanoscale Supramolecular Therapeutics with Increased Anticancer Efficacy
In
the chemical world, evolution is mirrored in the origin of nanoscale
supramolecular structures from molecular subunits. The complexity
of function acquired in a supramolecular system over a molecular subunit
can be harnessed in the treatment of cancer. However, the design of
supramolecular nanostructures is hindered by a limited atomistic level
understanding of interactions between building blocks. Here, we report
the development of a computational algorithm, which we term Volvox
after the first multicellular organism, that sequentially integrates
quantum mechanical energy-state- and force-field-based models with
large-scale all-atomistic explicit water molecular dynamics simulations
to design stable nanoscale lipidic supramolecular structures. In one
example, we demonstrate that Volvox enables the design of a nanoscale
taxane supramolecular therapeutic. In another example, we demonstrate
that Volvox can be extended to optimizing the ratio of excipients
to form a stable nanoscale supramolecular therapeutic. The nanoscale
taxane supramolecular therapeutic exerts greater antitumor efficacy
than a clinically used taxane <i>in vivo</i>. Volvox can
emerge as a powerful tool in the design of nanoscale supramolecular
therapeutics for effective treatment of cancer